FDA 483 - Beigene (Suzhou) Co., Ltd. - June 16, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of BeiGene (Suzhou) Co., Ltd, a drug manufacturer, revealed significant deficiencies in laboratory controls, analytical method validation, data integrity practices, and equipment qualification. The firm failed to ensure scientifically sound test procedures, adequately validate an HPLC method, maintain data integrity for testing systems, and properly qualify a particle size meter. These issues indicate a lack of assurance in the quality and purity of their drug products.
ID · ea0358d7-576e-42a1-9d4e-45def2af5b8e